High-Risk SCC in Transplant and Immunosuppressed Patients

Who Is Considered Immunosuppressed?

Immune suppression can come from solid-organ transplantation, CLL or another hematologic malignancy, stem-cell transplantation, HIV, or medications used for autoimmune and inflammatory disease. These groups do not share one uniform risk estimate or one treatment plan.

Why Immune Status Changes the SCC Conversation

After solid-organ transplantation, cSCC becomes much more common. A 2024 meta-analysis of 67 studies estimated a pooled standardized incidence ratio of 45.9, but the estimates ranged from roughly fivefold to more than 200-fold.¹ Organ type, latitude, skin phenotype, medication regimen, era, and time since transplant all change the number. A single universal multiplier is misleading.

The most practical consequence is cumulative burden. A patient may develop many tumors over time, which increases the chance that one will carry aggressive features and makes prevention, surveillance, and treatment coordination increasingly important.²

Whether immune suppression independently makes one stage-matched tumor more likely to metastasize remains unsettled. Studies conflict, although current NCCN treatment guidance includes immune suppression as a risk feature.^3,4 That uncertainty should not be turned into false reassurance or fear. The right response is earlier attention, complete risk assessment, and treatment that matches the individual tumor.

CLL and other blood cancers, stem-cell transplantation, HIV, and chronic immune-modifying medicines also raise cSCC concern, but they do not share one transplant-derived risk number.⁵ The cause and depth of immune suppression, prior skin-cancer burden, and the tumor's own features all matter.

Warning Signs That Deserve Prompt Evaluation

Contact a dermatologist promptly for a lesion that is:

• growing quickly;
• painful, tender, numb, tingling, or associated with weakness;
• bleeding or repeatedly crusting;
• thick, firm, or horn-like;
• nonhealing;
• recurring in a previously treated site; or
• accompanied by a new lump in a nearby lymph-node basin.

These signs do not prove that a lesion is dangerous. They change the cost of waiting. In an immunosuppressed patient, a changing or painful scaly spot should be treated as a medical question, not dismissed as an ordinary sun spot.

How Treatment Planning Changes

The clinician should combine immune status with the tumor's size, depth, location, borders, recurrence history, pathology, nerve involvement, and nodal examination. Mohs or another complete-margin method is often considered when these features raise the cost of residual tumor. It is not automatically required for every SCC in every immunosuppressed patient.

When recurrence or metastatic consequences would be especially serious, complete margin assessment can be more valuable because an uncertain local edge carries a higher cost.

Treatment planning often includes:

1. Complete pathology context. Depth, differentiation, perineural invasion, lymphovascular invasion, invasion beyond fat, and margin status can change the pathway.
2. A deliberate nodal and nerve examination. The skin tumor is only one part of the examination when risk is high.
3. Imaging when it can change care. CT can help stage lymph nodes; MRI is preferred when perineural spread is suspected; ultrasound can assess a superficial nodal basin.^3,6
4. Margin strategy that fits the risk. Mohs or another complete-margin method is often considered when borders, recurrence, anatomy, pathology, or immune status make residual tumor especially costly.³
5. Multidisciplinary coordination. Radiation oncology, medical oncology, transplant medicine, hematology, or infectious-disease expertise may enter selectively.

Immune suppression is not an automatic command that every SCC must be treated with Mohs regardless of site or pathology. It is a reason to make the classification and margin decision more deliberately.

Sentinel lymph-node biopsy is not routine standard care. It may be discussed for selected clinically node-negative very-high-risk tumors, but current guidance reflects nonuniform consensus rather than a universal rule.³

Prevention and Surveillance That Match the Risk

Surveillance

Follow-up should reflect tumor risk, immune status, and the pace of new cancers. Visits are generally most frequent during the first two years after a higher-risk cSCC and may then be spaced over time.³ A patient with repeated tumors may need closer skin surveillance than a patient with one lower-risk lesion.

No randomized trial establishes one perfect interval, and “every three months indefinitely” is not a rule for every transplant recipient.⁷

Sun and field protection

UV protection remains the foundation: protective clothing, shade, sunscreen on exposed skin, avoidance of tanning, and prompt evaluation of changing lesions. Field cancerization may be treated with topical 5-fluorouracil, imiquimod, photodynamic therapy, or other dermatologist-directed methods when appropriate. These treatments can reduce precancers or selected surface disease; they do not replace definitive treatment of an invasive higher-risk SCC.⁸

Acitretin

Acitretin can reduce keratinocyte-cancer burden in selected kidney-transplant recipients with repeated tumors. The evidence comes from small trials, benefit wanes after stopping, and dryness, lipid and liver effects, monitoring, and strict pregnancy constraints limit its use.^8,9

Nicotinamide

Nicotinamide reduced keratinocyte cancers in a high-risk immunocompetent trial, but the 2023 ONTRANS trial found no benefit in solid-organ transplant recipients.^10,11 The immunocompetent result should not be transferred to transplant patients as though the populations were interchangeable.

Changing immunosuppression

In selected kidney-transplant recipients with prior cSCC, conversion from a calcineurin-inhibitor regimen to sirolimus reduced new cSCC.¹² The tradeoff is real: tolerability is limited, and a large individual-participant meta-analysis identified increased mortality.¹³ Evidence from kidney recipients cannot be generalized automatically to every transplanted organ.

Do not stop or change antirejection or immune-modifying medicine because of something you read online. Reducing one risk can create another. Medication changes belong to a coordinated decision with the transplant or prescribing team.

When Advanced Treatment Requires a Transplant Team

PD-1 checkpoint inhibitors can produce meaningful responses in advanced cSCC, but they can also cause the immune system to attack a transplanted organ.

A 2025 individual-participant meta-analysis included 343 solid-organ transplant recipients with advanced cancers, 110 of whom had cSCC. For the cSCC subgroup, the objective response rate was 61%, while six-month acute rejection was 23.3%.¹⁴ Across the broader transplant cohort, one-year rejection was 36.2% and graft loss was 18.4%.¹⁴

A small phase I study treated 12 kidney-transplant recipients with advanced cSCC using cemiplimab plus a specific mTOR- and steroid-based immunosuppression protocol. The response rate was 46%, with no rejection or graft loss observed in those 12 participants.¹⁵ This is promising but too small and organ-specific to promise safety for everyone.

Your Coordinated-Care Checklist

• Bring the full pathology report, not only the diagnosis name.
• Ask whether depth, differentiation, nerve involvement, lymphovascular invasion, and margins were assessed.
• Tell the dermatologist exactly why you are immunosuppressed and which medicines you take.
• Ask whether a nodal examination, imaging, radiation, or oncology review is needed.
• Ask what follow-up interval fits your tumor burden and immune status.
• Keep the transplant or prescribing team involved before any medication change.

Why Complete Margin Assessment Matters More Here

An immunosuppressed patient does not merely have more SCCs; the cancers can behave more aggressively and recur more often. For a resectable high-risk tumor, Mohs offers the most complete local margin information while preserving tissue for future tumors and repairs. That makes Mohs a particularly strong option when the tumor is recurrent, poorly defined, rapidly growing, or located in high-stakes anatomy.

There is not yet a transplant-only randomized trial proving a survival advantage from Mohs. That gap should not be used to pretend the margin methods are equivalent. The biologic risk is higher, and the clinical value of knowing the complete margin is correspondingly greater.

How Immune Suppression Changes the Plan

Next Steps in the Patient Journey

Continue with the focused guide that matches the tumor risk, treatment plan, and immune status.